Ipsen Aktie

99,20 EUR -0,15 EUR -0,15 %

15:01:36

STU

92,77 CHF +0,12 CHF +0,13 %

15:47:20

BRX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.8,21 Mrd. EUR

KGV26,49Div. Rendite1,26%

WKNA0ESMG

ISINFR0010259150

SymbolIPSEF

Ipsen Aktien News

Sortieren:Datum Meistgelesen

13.11.23PR NewswireIpsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

07.11.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2023

06.11.23GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

31.10.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 43 - 2023

27.10.23finanzen.netIpsen: Was beim Unternehmen in den jüngsten Büchern steht

27.10.23finanzen.netIpsen (spons ADRs): Bilanzvorlage zum letzten Quartal

26.10.23GlobeNewswireIpsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

24.10.23GlobeNewswireIPSEN - Buy-back program - Art 5 of MAR - Week 42 - 2023

23.10.23GlobeNewswireIpsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome

17.10.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 41 - 2023

10.10.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 40 - 2023

06.10.23GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

03.10.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2023

03.10.23GlobeNewswireIpsen updates on QM-1114 regulatory process

26.09.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2023

19.09.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2023

12.09.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 36 - 2023

08.09.23GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

05.09.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2023

04.09.23GlobeNewswireIpsen nominates Pascal Touchon to its Board of Directors as new independent director

01.09.23GlobeNewswireIpsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet

29.08.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2023

22.08.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2023

21.08.23GlobeNewswireExelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

16.08.23GlobeNewswireUS FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva

16.08.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2023

08.08.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2023

04.08.23GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

01.08.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2023

27.07.23GlobeNewswireIpsen S.A. publishes its 2023 Half-Year Financial Report

27.07.23GlobeNewswireIpsen delivers solid H1 2023 results and upgrades its full-year guidance

25.07.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2023

24.07.23GlobeNewswireIpsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023

21.07.23GlobeNewswireIpsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome

19.07.23GlobeNewswireIpsen announces European Commission decision on palovarotene for the treatment of FOP

18.07.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2023

11.07.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2023

Ipsen News

Ipsen News: auf dieser Seite finden Sie alle Ipsen News und Nachrichten zur Ipsen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ipsen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ipsen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.